Vaccination and modern management of chronic obstructive pulmonary disease – a narrative review

References

• WHO. 2018. The top 10 causes of death: World Health Organization. [cited 2022 Jun 21]. Available from: http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
   Google Scholar
• Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018 Nov 10;392(10159): 1789–1858.
   PubMedGoogle Scholar
• Vogelmeier CF, Diesing J, Kossack N, et al. COPD exacerbation history and impact on future exacerbations – 8-year retrospective observational database cohort study from Germany. Int J Chron Obstruct Pulmon Dis. 2021;16:2407–2417.
   PubMed Web of Science ®Google Scholar
• Burke H, Wilkinson TMA. Unravelling the mechanisms driving multimorbidity in COPD to develop holistic approaches to patient-centred care. Eur Respir Rev. 2021 Jun 30;30(160):160.
   Google Scholar
• Bouquet J, Tabor DE, Silver JS, et al. Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort. Respir Res. 2020 Mar 30;21(1):77.
   PubMed Web of Science ®Google Scholar
• Sethi S, Wrona C, Eschberger K, et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 Mar 1;177(5):7–491.
   Google Scholar
• Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007 Sep 1;370(9589):96–786.
   Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012 Nov;67(11):63–957.
   Google Scholar
• McGhan R, Radcliff T, Fish R, et al. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest. 2007 Dec;132(6):55–1748.
   Google Scholar
• Mayhew D, Devos N, Lambert C, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax. 2018 May;73(5):422–430.
   PubMed Web of Science ®Google Scholar
• Huang YJ, Sethi S, Murphy T, et al. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol. 2014 Aug;52(8):23–2813.
   Google Scholar
• Weeks JR, Staples KJ, Spalluto CM, et al. The role of non-typeable Haemophilusinfluenzae biofilms in chronic obstructive pulmonary disease. Front Cell Infect Microbiol. 2021;11:720742.
   PubMedGoogle Scholar
• Hinks TS, Wallington JC, Williams AP, et al. Steroid-induced deficiency of mucosal-associated invariant T cells in the chronic obstructive pulmonary disease lung. Implications for nontypeable Haemophilusinfluenzae infection. Am J Respir Crit Care Med. 2016 Nov 15;194(10):1208–1218.
   PubMedGoogle Scholar
• Singanayagam A, Glanville N, Girkin JL, et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nat Commun. 2018 Jun 8;9(1):2229.
   PubMed Web of Science ®Google Scholar
• Wilkinson TMA, Aris E, Bourne S, et al. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. Thorax. 2017 Oct;72(10):919–927.
   PubMed Web of Science ®Google Scholar
• Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Nov 1;164(9):23–1618.
   Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch Bronconeumol. 2017 Mar;53(3):128–149.
   PubMed Web of Science ®Google Scholar
• Mathioudakis AG, Janssens W, Sivapalan P, et al. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax. 2020 Jun;75(6):520–527.
   PubMed Web of Science ®Google Scholar
• Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018 Mar 31;391(10127):1285–1300.
   PubMed Web of Science ®Google Scholar
• Nguyen JL, Yang W, Ito K, et al. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol. 2016 Jun 1;1(3):81–274.
   Google Scholar
• Sandoval C, Walter SD, Krueger P, et al. Risk of hospitalization during influenza season among a cohort of patients with congestive heart failure. Epidemiol Infect. 2007 May;135(4):82–574.
   Google Scholar
• Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018 Jan 25;378(4):345–353.
   PubMed Web of Science ®Google Scholar
• Chow EJ, Rolfes MA, O’Halloran A, et al. Acute cardiovascular events associated with influenza in hospitalized adults: a cross-sectional study. Ann Intern Med. 2020 Oct 20;173(8):605–613.
   PubMed Web of Science ®Google Scholar
• Macias AE, McElhaney JE, Chaves SS, et al. The disease burden of influenza beyond respiratory illness. Vaccine. 2021 Mar 15;39(Suppl 1):A6–A14.
   PubMed Web of Science ®Google Scholar
• Fischer WA 2nd, Gong M, Bhagwanjee S, et al. Global burden of influenza as a cause of cardiopulmonary morbidity and mortality. Glob Heart. 2014 9; Sep(3): 36–325.
   Google Scholar
• Mohan A, Chandra S, Agarwal D, et al. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology. 2010 Apr;15(3):42–536.
   Google Scholar
• Jang JG, Ahn JH, Jin HJ. Incidence and prognostic factors of respiratory viral infections in severe acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;16:1265–1273.
   PubMed Web of Science ®Google Scholar
• Chen CC, Lin CH, Hao WR, et al. Influenza vaccination and the risk of ventricular arrhythmias in patients with chronic obstructive pulmonary disease: a population-based longitudinal study. Front Cardiovasc Med. 2021;8:731844.
   PubMedGoogle Scholar
• Mulpuru S, Li L, Ye L, et al. Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD. Chest. 2019 Jan;155(1):69–78.
   PubMed Web of Science ®Google Scholar
• Kopsaftis Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018 Jun;26(6):CD002733.
   Google Scholar
• Wongsurakiat P, Maranetra KN, Wasi C, et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest. 2004 Jun;125(6):20–2011.
   Google Scholar
• WHO Regional. Office for Europe recommendations on influenza vaccination for the 2020/2021 season during the ongoing COVID-19 pandemic. Copenhagen: Wolrd Health Organisation; 2020.
   Google Scholar
• Centers for Disease Control and Prevention: people at higher risk of flu complications. 2021. [cited 2022 Jun 21]. Available from: https://www.cdc.gov/flu/highrisk/index.htm
   Google Scholar
• European Centre for Disease Prevention and Control: Priority risk groups for influenza vaccination Stockholm 2008.
   Google Scholar
• OECD. Influenza vaccination rates (indicator). 2021. [cited 2022 Jun 21]. Available from: https://data.oecd.org/healthcare/influenza-vaccination-rates.htm.
   Google Scholar
• Saeed GJ, Valero-Elizondo J, Mszar R, et al. Prevalence and disparities in influenza vaccination among patients with COPD in the United States. Chest. 2021 Apr;159(4):1411–1414.
   PubMedGoogle Scholar
• Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016 Aug;16(8):51–942.
   Google Scholar
• McElhaney JE, Verschoor CP, Andrew MK, et al. The immune response to influenza in older humans: beyond immune senescence. Immun Ageing. 2020;17(1):10.
   PubMedGoogle Scholar
• Paudel M, Mahmud S, Buikema A, et al. Relative vaccine efficacy of high-dose versus standard-dose influenza vaccines in preventing probable influenza in a medicare fee-for-service population. Vaccine. 2020 Jun 15;38(29):4548–4556.
   PubMedGoogle Scholar
• Balasubramani GK, Choi WS, Nowalk MP, et al. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19. Vaccine. 2020 Sep 29;38(42):6562–6569.
   PubMedGoogle Scholar
• Lee JKH, Lam GKL, Shin T, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines. 2018 May;17(5):435–443.
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014 Aug 14;371(7):45–635.
   Google Scholar
• Gravenstein S, McConeghy KW, Saade E, et al. Adjuvanted influenza vaccine and influenza outbreaks in U.S. nursing homes: results from a pragmatic cluster-randomized clinical trial. Clin Infect Dis. 2021 Jan 5;73(11):e4229–e4236.
   PubMedGoogle Scholar
• McConeghy KW, Davidson HE, Canaday DH, et al. Cluster-randomized trial of adjuvanted vs. non-adjuvanted trivalent influenza vaccine in 823 U.S. nursing homes. Clin Infect Dis. 2020 Sep 4;71(8):e202–e205.
   PubMedGoogle Scholar
• So JY, O’Hara NN, Kenaa B, et al. Population decline in COPD admissions during the COVID-19 pandemic associated with lower burden of community respiratory viral infections. Am J Med. 2021 Oct;134(10):1252–1259 e3.
   PubMed Web of Science ®Google Scholar
• Tan JY, Conceicao EP, Sim XYJ, et al. Public health measures during COVID-19 pandemic reduced hospital admissions for community respiratory viral infections. J Hosp Infect. 2020 Oct;106(2):387–389.
   PubMedGoogle Scholar
• Huh K, Kim YE, Ji W, et al. Decrease in hospital admissions for respiratory diseases during the COVID-19 pandemic: a nationwide claims study. Thorax. 2021 Sep;76(9):939–941.
   PubMedGoogle Scholar
• Gonzalez J, Moncusi-Moix A, Benitez ID, et al. Clinical consequences of COVID-19 lockdown in patients with COPD: results of a pre-post study in Spain. Chest. 2021 Jul;160(1):135–138.
   PubMed Web of Science ®Google Scholar
• Alqahtani JS, Oyelade T, Aldhahir AM, et al. Reduction in hospitalised COPD exacerbations during COVID-19: a systematic review and meta-analysis. PLoS One. 2021;16(8):e0255659.
   PubMedGoogle Scholar
• Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):May.
   Google Scholar
• Attaway AA, Zein J, Hatipoglu US, SARS-CoV-2. infection in the COPD population is associated with increased healthcare utilization: an analysis of Cleveland clinic’s COVID-19 registry. EClinicalMedicine. 2020 Sep;26:100515.
   PubMedGoogle Scholar
• Meza D, Khuder B, Bailey JI, et al. Mortality from COVID-19 in patients with COPD: a US study in the N3C data enclave. Int J Chron Obstruct Pulmon Dis. 2021;16:2323–2326.
   PubMed Web of Science ®Google Scholar
• Beltramo G, Cottenet J, Mariet AS, et al. Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study. Eur Respir J. 2021 May 20;58(6):2004474.
   PubMedGoogle Scholar
• Schultze A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020 Nov;8(11):1106–1120.
   PubMed Web of Science ®Google Scholar
• Lewis NM, Naioti EA, Self WH, et al. Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age and burden of chronic medical conditions among immunocompetent US adults, March-August 2021. J Infect Dis. 2021 Dec 21;224(8):1362–1371.
   PubMedGoogle Scholar
• Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021 Apr 15;384(15):1412–1423.
   PubMed Web of Science ®Google Scholar
• Liao SY, Gerber AN, Zelarney P, et al. Impaired SARS-CoV-2 mRNA vaccine antibody response in chronic medical conditions: a real-world analysis. Chest. 2022 Jan 10;161(6):1490–1493.
   PubMedGoogle Scholar
• Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021 Jun;21(6):395–404.
   PubMed Web of Science ®Google Scholar
• Kandeil W, Atanasov P, Avramioti D, et al. The burden of pertussis in older adults: what is the role of vaccination? A systematic literature review. Expert Rev Vaccines. 2019 May;18(5):439–455.
   PubMed Web of Science ®Google Scholar
• Moore A, Harnden A, Grant CC, et al. Clinically diagnosing pertussis-associated cough in adults and children: CHEST guideline and expert panel report. Chest. 2019 Jan;155(1):147–154.
   PubMed Web of Science ®Google Scholar
• Jenkins VA, Savic M, Kandeil W. Pertussis in high risk groups: an overview of the past quarter century. Hum Vaccin Immunother. 2020 Nov 1;16(11):2609–2617.
   PubMed Web of Science ®Google Scholar
• Laboratory confirmed cases of pertussis in England: annual report for 2019. Health protection report: Public Health England; 2019.
   Google Scholar
• Tong J, Buikema A, Horstman T. Epidemiology and disease burden of pertussis in the United States among individuals aged 0-64 over a 10-year period (2006-2015). Curr Med Res Opin. 2020 Jan;36(1):127–137.
   PubMed Web of Science ®Google Scholar
• Aris E, Harrington L, Bhavsar A, et al. Burden of pertussis in COPD: a retrospective database study in England. COPD. 2021 Apr;18(2):157–169.
   PubMedGoogle Scholar
• Buck PO, Meyers JL, Gordon LD, et al. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims. Epidemiol Infect. 2017 Jul;145(10):2109–2121.
   PubMed Web of Science ®Google Scholar
• Bonhoeffer J, Bar G, Riffelmann M, et al. The role of bordetella infections in patients with acute exacerbation of chronic bronchitis. Infection. 2005 Feb;33(1):7–13.
   Google Scholar
• Mullerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012 Aug;106(8):33–1124.
   Google Scholar
• Torres A, Peetermans WE, Viegi G, et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013 Nov;68(11):65–1057.
   Google Scholar
• Bornheimer R, Shea KM, Sato R, et al. Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary disease. PLoS One. 2017;12(10):e0184877.
   PubMed Web of Science ®Google Scholar
• Lin VY, Kaza N, Birket SE, et al. Excess mucus viscosity and airway dehydration impact COPD airway clearance. Eur Respir J. 2020 Jan;55(1):1900419.
   PubMedGoogle Scholar
• Teerapuncharoen K, Wells JM, Raju SV, et al. Acquired cystic fibrosis transmembrane conductance regulator dysfunction and radiographic bronchiectasis in current and former smokers: a cross-sectional study. Ann Am Thorac Soc. 2019 Jan;16(1):150–153.
   PubMed Web of Science ®Google Scholar
• Shukla SD, Muller HK, Latham R, et al. Platelet-activating factor receptor (PAFr) is upregulated in small airways and alveoli of smokers and COPD patients. Respirology. 2016 Apr;21(3):10–504.
   PubMedGoogle Scholar
• Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018 Jun;16(6):355–367.
   PubMed Web of Science ®Google Scholar
• Fernandez-Delgado L, Camara J, Gonzalez-Diaz A, et al. Serotypes in adult pneumococcal pneumonia in Spain in the era of conjugate vaccines. Microorganisms. 2021 Oct 28;9(11):2245.
   PubMedGoogle Scholar
• Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015 May;15(5):43–535.
   Google Scholar
• Domenech A, Ardanuy C, Tercero A, et al. Dynamics of the pneumococcal population causing acute exacerbations in COPD patients in a Barcelona hospital (2009-12): comparison with 2001-04 and 2005-08 periods. J Antimicrob Chemother. 2014 Apr;69(4):9–932.
   Google Scholar
• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009 Mar;9(3):20–213.
   Google Scholar
• Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018 Apr;18(4):441–451.
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015 Mar 19;372(12):25–1114.
   Google Scholar
• Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017;12(1):e0169368.
   PubMed Web of Science ®Google Scholar
• Walters JA, Tang JN, Poole P, et al. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Jan;24(1):CD001390.
   Google Scholar
• Heo JY, Seo YB, Choi WS, et al. Effectiveness of pneumococcal vaccination against pneumococcal pneumonia hospitalization in older adults: a prospective, test-negative study. J Infect Dis. 2021;225(5):836–845 .
   Google Scholar
• Papadatou I, Spoulou V. Pneumococcal vaccination in high-risk individuals: are we doing it right? Clin Vaccine Immunol. 2016 May;23(5):388–395.
   PubMedGoogle Scholar
• Hurley D, Griffin C, Young M, et al. Safety, tolerability, and immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in adults 60 to 64 years of age. Clin Infect Dis. 2021 Oct 5;73(7):e1489–e1497.
   PubMedGoogle Scholar
• Klein NP, Peyrani P, Yacisin K, et al. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine. 2021 Sep 7;39(38):5428–5435.
   PubMed Web of Science ®Google Scholar
• Prasad N, Newbern EC, Trenholme AA, et al. The health and economic burden of respiratory syncytial virus associated hospitalizations in adults. PLoS One. 2020;15(6):e0234235.
   PubMed Web of Science ®Google Scholar
• Ackerson B, Tseng HF, Sy LS, et al. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clin Infect Dis. 2019 Jul 2;69(2):197–203.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005 Apr 28;352(17):59–1749.
   Google Scholar
• Crank MC, Ruckwardt TJ, Chen M, et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science. 2019 Aug 2;365(6452):505–509.
   PubMed Web of Science ®Google Scholar
• Powell K. 2021. The race to make vaccines for a dangerous respiratory virus: nature.[2021 December 21]. Available from: https://www.nature.com/articles/d41586-021-03704-y
   Google Scholar
• Teo E, Lockhart K, Purchuri SN, et al. Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Jun;19(6):CD010010.
   Google Scholar
• Wilkinson TMA, Schembri S, Brightling C, et al. Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: a phase 2 clinical trial. Vaccine. 2019 Sep 24;37(41):6102–6111.
   PubMedGoogle Scholar
• Perez AC, Murphy TF. A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: an update on current progress and challenges. Hum Vaccin Immunother. 2017 Oct 3;13(10):2322–2331.
   PubMed Web of Science ®Google Scholar
• Kadry NA, Porsch EA, Shen H, et al. Immunization with HMW1 and HMW2 adhesins protects against colonization by heterologous strains of nontypeable Haemophilus influenzae. Proc Natl Acad Sci U S A. 2021 Aug 10;118(32). DOI:https://doi.org/10.1073/pnas.2019923118.
   Google Scholar
• Andreas S, Testa M, Boyer L, et al. Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial. Lancet Respir Med. 2022 Jan;10(1):10.
   PubMedGoogle Scholar
• Eklof J, Sorensen R, Ingebrigtsen TS, et al. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients. Clin Microbiol Infect. 2020 Feb;26(2):227–234.
   PubMed Web of Science ®Google Scholar
• Jacobs DM, Ochs-Balcom HM, Noyes K, et al. Impact of Pseudomonas aeruginosa Isolation on mortality and outcomes in an outpatient chronic obstructive pulmonary disease cohort. Open Forum Infect Dis. 2020 Jan;71:546. ofz.
   Google Scholar
• Tummler B. Emerging therapies against infections with Pseudomonas aeruginosa. F1000Res. 2019;8.
   Google Scholar
• Proctor LL, Ward WL, Roggy CS, et al. Potential therapeutic targets for combination antibody therapy against Pseudomonas aeruginosa infections. Antibiotics (Basel). 2021 Dec 14;10(12). https://doi.org/10.3390/antibiotics10121530.
   Google Scholar
• Hoggarth A, Weaver A, Pu Q, et al. Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa. Drug Des Devel Ther. 2019;13:909–924.
   PubMed Web of Science ®Google Scholar
• Priebe GP, Goldberg JB. Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines. 2014 Apr;13(4):19–507.
   Google Scholar
• Grimwood K, Kyd JM, Owen SJ, et al. Vaccination against respiratory Pseudomonas aeruginosa infection. Hum Vaccin Immunother. 2015;11(1):14–20.
   PubMed Web of Science ®Google Scholar
• Wang Z, Locantore N, Haldar K, et al. Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations: a multicohort longitudinal analysis. Am J Respir Crit Care Med. 2021 Jun 15;203(12):1488–1502.
   PubMed Web of Science ®Google Scholar
• Adlbrecht C, Wurm R, Depuydt P, et al. Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial. Crit Care. 2020 Mar 4;24(1):74.
   PubMedGoogle Scholar
• Rello J, Krenn CG, Locker G, et al. A randomized placebo-controlled phase II study of a pseudomonas vaccine in ventilated ICU patients. Crit Care. 2017 Feb 4;21(1):22.
   PubMedGoogle Scholar
• Dicker AJ, Huang JTJ, Lonergan M, et al. The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2021 Jan;147(1):158–167.
   PubMed Web of Science ®Google Scholar
• Keir HR, Dicker A, Lonergan M, et al. Clinical endotypes of exacerbation are associated with differences in microbial composition and diversity in COPD. Eur Respir J. 2020 Oct;56(4):2000391.
   PubMedGoogle Scholar
• Beech A, Lea S, Li J, et al. Airway bacteria quantification using polymerase chain reaction combined with neutrophil and eosinophil counts identifies distinct COPD endotypes. Biomedicines. 2021 Sep 27;9(10):1337.
   PubMed Web of Science ®Google Scholar
• Kim VL, Coombs NA, Staples KJ, et al. Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort. Eur Respir J. 2017 Oct;50(4):4.
   Google Scholar
• Bentley AM, Hamid Q, Robinson DS, et al. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med. 1996 Feb;153(2):6–551.
   Google Scholar
• Belchamber KB, Thomas CM, Dunne AE, et al. Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function. Int J Chron Obstruct Pulmon Dis. 2018;13:2883–2897.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018 May 3;378(18):1671–1680.
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011 Aug 25;365(8):98–689.
   Google Scholar
• Keir HR, Shoemark A, Dicker AJ, et al. Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. Lancet Respir Med. 2021 Aug;9(8):873–884.
   PubMed Web of Science ®Google Scholar
• Tsai WC, Rodriguez ML, Young KS, et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med. 2004 Dec 15;170(12):9–1331.
   Google Scholar
• Culic O, Erakovic V, Cepelak I, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002 Aug 30;450(3):277–289.
   PubMed Web of Science ®Google Scholar
• Pezzuto A, Carico E. Effectiveness of smoking cessation in smokers with COPD and nocturnal oxygen desaturation: functional analysis. Clin Respir J. 2020 Jan;14(1):29–34.
   PubMedGoogle Scholar
• Godtfredsen NS, Lam TH, Hansel TT, et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J. 2008 Oct;32(4):53–844.
   PubMedGoogle Scholar
• Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005 Feb 15;142(4):9–233.
   Google Scholar
• Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):90–381.
   Google Scholar
• Tottenborg SS, Thomsen RW, Johnsen SP, et al. Determinants of smoking cessation in patients with COPD treated in the outpatient setting. Chest. 2016 Sep;150(3):62–554.
   Google Scholar
• Andelius DK, Hilberg O, Ibsen R, et al. National epidemiological case-control study of pharmacological smoking cessation treatment in Danish patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;16:2433–2443.
   PubMed Web of Science ®Google Scholar
• Tottenborg SS, Clark AJ, Thomsen RW, et al. Socioeconomic inequality in the use of prescription medications for smoking cessation among patients with COPD: a nationwide study. Int J Chron Obstruct Pulmon Dis. 2018;13:1775–1781.
   PubMed Web of Science ®Google Scholar
• West R, Raw M, McNeill A, et al. Health-care interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national guideline development. Addiction. 2015 Sep;110(9):403–1388.
   Google Scholar
• Stead LF, Koilpillai P, Fanshawe TR, et al. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2016 Mar;24(3):CD008286.
   Google Scholar
• Park ER, Gareen IF, Japuntich S, et al. Primary care provider-delivered smoking cessation interventions and smoking cessation among participants in the national lung screening trial. JAMA Intern Med. 2015 Sep;175(9):16–1509.
   PubMedGoogle Scholar
• Layden JE, Ghinai I, Pray I, et al. Pulmonary Illness related to E-cigarette use in Illinois and Wisconsin - final report. N Engl J Med. 2020 Mar 5;382(10):903–916.
   PubMed Web of Science ®Google Scholar
• Eam VE, Bech Risor M, Spigt M, et al. Why do physicians lack engagement with smoking cessation treatment in their COPD patients? A multinational qualitative study. NPJ Prim Care Respir Med. 2017 Jun 23;27(1):41.
   PubMedGoogle Scholar
• Molin KR, Sondergaard J, Lange P, et al. Danish general practitioners’ management of patients with COPD: a nationwide survey. Scand J Prim Health Care. 2020 Dec;38(4):391–398.
   PubMed Web of Science ®Google Scholar
• Ebbert JO, Hughes JR, West RJ, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA. 2015 Feb 17;313(7):94–687.
   PubMedGoogle Scholar
• Rennard S, Hughes J, Cinciripini PM, et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res. 2012 Mar;14(3):50–343.
   Google Scholar
• Hughes JR, Rennard SI, Fingar JR, et al. Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial. Nicotine Tob Res. 2011 Oct;13(10):64–955.
   PubMedGoogle Scholar
• Steinberg ML, Lu SE, Williams JM. Varenicline for smoking reduction in smokers not yet ready to quit: a double-blind, proof-of-concept randomized clinical trial. Addict Behav. 2018 Sep;84:20–26.
   PubMedGoogle Scholar
• Leone FT, Zhang Y, Evers-Casey S, et al. Initiating pharmacologic treatment in tobacco-dependent adults. An official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 Jul 15;202(2):e5–e31.
   PubMed Web of Science ®Google Scholar
• Baker TB, Piper ME, Stein JH, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a randomized clinical trial. JAMA. 2016 Jan 26;315(4):9–371.
   Google Scholar
• Zhang L, Sun Y. Muscle-bone crosstalk in chronic obstructive pulmonary disease. Front Endocrinol (Lausanne). 2021;12:724911.
   PubMedGoogle Scholar
• Borghi-Silva A, Garcia-Araujo AS, Winkermann E, et al. Exercise-based rehabilitation delivery models in comorbid chronic pulmonary disease and chronic heart failure. Front Cardiovasc Med. 2021;8:729073.
   PubMedGoogle Scholar
• McCarthy B, Casey D, Devane D, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015 Feb;23(2):CD003793.
   Google Scholar
• Puhan MA, Gimeno-Santos E, Cates CJ, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Dec;8(12):CD005305.
   Google Scholar
• Stone PW, Hickman K, Steiner MC, et al. Predictors of referral to pulmonary rehabilitation from UK primary care. Int J Chron Obstruct Pulmon Dis. 2020;15:2941–2952.
   PubMed Web of Science ®Google Scholar
• Moore E, Newson R, Joshi M, et al. Effects of pulmonary rehabilitation on exacerbation number and severity in people with COPD: an historical cohort study using electronic health records. Chest. 2017 Dec;152(6):1188–1202.
   PubMedGoogle Scholar
• Rassouli F, Germann A, Baty F, et al. Telehealth mitigates COPD disease progression compared to standard of care: a randomized controlled crossover trial. J Intern Med. 2021 Mar;289(3):404–410.
   PubMedGoogle Scholar
• Metting E, Dassen L, Aardoom J, et al. Effectiveness of telemonitoring for respiratory and systemic symptoms of asthma and COPD: a narrative review. Life (Basel). 2021 Nov 10;11(11). https://doi.org/10.3390/life11111215.
   Google Scholar
• Godtfredsen N, Frolich A, Bieler T, et al. 12-months follow-up of pulmonary tele-rehabilitation versus standard pulmonary rehabilitation: a multicentre randomised clinical trial in patients with severe COPD. Respir Med. 2020 Oct;172:106129.
   PubMed Web of Science ®Google Scholar
• Hansen H, Bieler T, Beyer N, et al. Supervised pulmonary tele-rehabilitation versus pulmonary rehabilitation in severe COPD: a randomised multicentre trial. Thorax. 2020 May;75(5):413–421.
   PubMed Web of Science ®Google Scholar
• Gillenwater LA, Helmi S, Stene E, et al. Multi-omics subtyping pipeline for chronic obstructive pulmonary disease. PLoS One. 2021;16(8):e0255337.
   PubMedGoogle Scholar
• DeMeo DL. Sex and gender omic biomarkers in men and women with COPD: considerations for precision medicine. Chest. 2021 Jul;160(1):104–113.
   PubMedGoogle Scholar
• Prokic I, Lahousse L, de Vries M, et al. A cross-omics integrative study of metabolic signatures of chronic obstructive pulmonary disease. BMC Pulm Med. 2020 Jul 16;20(1):193.
   PubMed Web of Science ®Google Scholar